Omeros (OMER) – Research Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Omeros (NASDAQ: OMER):

• 11/20/2024 – Omeros was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 11/14/2024 – Omeros was upgraded by analysts at RODMAN&RENSHAW to a “strong-buy” rating.
• 11/14/2024 – Omeros had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald.
• 11/14/2024 – Omeros had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 11/14/2024 – Omeros is now covered by analysts at Rodman & Renshaw. They set a “buy” rating and a $9.00 price target on the stock.
• 11/12/2024 – Omeros was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.

Omeros Trading Down 4.7 %

NASDAQ OMER opened at $11.35 on Monday. The company has a market cap of $657.73 million, a P/E ratio of -4.91 and a beta of 1.47. The company has a fifty day simple moving average of $5.29 and a 200 day simple moving average of $4.52. Omeros Co. has a 12-month low of $1.97 and a 12-month high of $12.49.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its position in Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 7,016 shares in the last quarter. MML Investors Services LLC lifted its holdings in shares of Omeros by 19.2% in the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 3,000 shares in the last quarter. SPC Financial Inc. purchased a new position in shares of Omeros during the third quarter valued at approximately $77,000. SG Americas Securities LLC purchased a new position in shares of Omeros during the third quarter valued at approximately $80,000. Finally, Comerica Bank grew its holdings in Omeros by 20.0% during the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 5,000 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.